Login to Your Account

Genentech paves path to anti-PDL1 filing with pivotal NSCLC study

By Michael Fitzhugh
Staff Writer

Monday, August 17, 2015

Genentech Inc.'s most advanced immunotherapy candidate, atezolizumab, met its primary endpoint in a pivotal phase II study, shrinking tumors in people with locally advanced or metastatic NSCLC whose disease expressed programmed cell death ligand-1, and setting the stage for an early 2016 registration filing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription